#China #Suzhou #Suzhou Ribo #Ribocure #Madrigal

Ribo and Madrigal's Collaborative Milestone

In a groundbreaking advancement for the treatment of metabolic associated steatohepatitis (MASH), Suzhou Ribo Life Science Co., Ltd. (06938.HK) and Madrigal Pharmaceuticals, Inc. have announced the successful achievement of their first candidate drug nomination within their collaborative effort focused on siRNA therapies. This partnership underscores a commitment to develop innovative therapeutic options that address significant unmet medical needs in the field of liver diseases.

The joint announcement, made on July 2, 2026, highlights the culmination of collaborative efforts that led to a pivotal milestone. This achievement paves the way for the immediate initiation of preclinical studies aimed at preparing for a clinical trial application (IND). Such initiatives are vital as they will support the upcoming planned clinical studies, thereby fostering hope for patients suffering from liver ailments, particularly MASH.

The collaboration between Ribo and Madrigal signifies a melding of expertise and innovation, merging Ribo’s premier capabilities in siRNA drug discovery and delivery technology with Madrigal's established clinical experience and market position in tackling MASH. Ribo’s co-CEO and Global Head of R&D, Li-Ming Gan, expressed enthusiasm regarding their joint progress, stating, “We are pleased to have reached this critical milestone in our joint MASH program with Madrigal in just a few months. Our complementary strengths are driving the rapid advancement of this project, and we are committed to accelerating the development of our new siRNA candidate for MASH.”

MASH represents a complex challenge in hepatology, characterized by liver inflammation due to fat accumulation, often linked to metabolic dysfunction. The current landscape shows significant medical need due to the lack of effective treatments. By focusing on innovative RNA interference (RNAi) technologies, Ribo aims to address this gap with promising preclinical assets in their pipeline.

Founded as a clinical-stage biotechnology company, Ribo has established itself as an innovator in the use of nucleic acid drugs and has focused on ways to leverage their RNAi technology for effective therapeutic solutions. Their commitment to medically relevant advancements has driven the rapid development of their therapeutic arsenal. Similarly, Ribocure Pharmaceuticals AB, a subsidiary of Ribo, dedicates itself to the global advancement of life-saving oligonucleotide therapies, ensuring that new groundbreaking insights translate into actionable treatment options.

As this partnership continues to unfold, the implications for patients suffering from MASH and other liver-related diseases are profound. Both companies are poised to make significant contributions towards new therapeutic pathways, offering hope to countless patients worldwide who are awaiting innovations that can transform their health outcomes.

For additional information on Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals, visit www.ribolia.com and www.ribocure.com.